antiangiogenic


Also found in: Dictionary, Wikipedia.
Related to antiangiogenic: Antiangiogenic Therapy

antiangiogenic

(ăn′tē-ăn′jē-ō-jĕn′ĭk, ăn′tī-)
adj.
Of or relating to a naturally occurring substance, drug, or other compound that can destroy or interfere with the fine network of blood vessels needed by tumors to grow and metastasize.
References in periodicals archive ?
Antiangiogenic activity of berberine is mediated through the downregulation of hypoxia-inducible factor-1, VEGF, and proinflammatory mediators.
Suppression of bone turnover, soft tissue toxicity, infection as a result of cellular response, ischaemia due to antiangiogenic effect of bisphosphonates are the theories of BRONJ pathophysiology.
This latter observation is not surprising, given that the antiangiogenic pathway is intimately involved in the disease pathogenesis and upstream of the resulting endothelial damage, such as an increased creatinine or transaminitis.
Furthermore, the antiangiogenic property was evaluated using ex vivo rat aorta ring assay.
Biomarkers of response and resistance to antiangiogenic therapy.
Blocking angiogenesis is a validated effective therapeutic approach against cancer, and several antiangiogenic agents (Avastin, Sutent, Nexavar, Votrient, Inlyta, Zaltrap, Stivarga, etc.) (Meadows and Hurwitz 2012; Mullard 2013) have been successfully translated into cancer clinic.
As a result, they developed a compound called Sphinx, which can switch the production of VEGF from the proangiogenic form to the antiangiogenic form to block the formation of new blood vessels, and cause the tumours to starve themselves, preventing the growth and spread of the cancer.
increase the total VEGF expression level, but differentially influence pro-angiogenic and antiangiogenic isoforms.
Hyperbaric oxygen (HBO) is effective when used in conjunction with other therapies and may neutralize the antiangiogenic effects of aminobisphosphonates.
A position paper on Medication Related Osteonecrosis of the Jaw (MRONJ), released by the American Association of Oral and Maxillofacial Surgeons, expands the scope of the condition previously referred to as Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) and changes its name to reflect the antiresorptive (denosumab) and antiangiogenic therapies that have recently been associated with the condition.
The agent is believed to augment neutrophil-killing ability on abnormal cells via damaging mitochondria, and its antiangiogenic properties promote healing and skin regeneration.